Opinercept Biosimilar – Anti-TNF fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2020; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Opinercept Biosimilar is a novel anti-TNF fusion protein that has shown promising results in the treatment of various inflammatory and autoimmune diseases. This biosimilar is a highly effective and safe alternative to currently available anti-TNF therapies, providing a new option for patients and healthcare providers.
Opinercept Biosimilar is a fusion protein that is composed of two components – a human IgG1 Fc region and a soluble TNF receptor 2 (sTNFR2) domain. This unique structure allows Opinercept Biosimilar to specifically target and inhibit the activity of TNF, a key cytokine involved in the pathogenesis of various inflammatory diseases.
The human IgG1 Fc region provides Opinercept Biosimilar with a long half-life and increased stability, ensuring a sustained therapeutic effect. On the other hand, the sTNFR2 domain acts as a decoy receptor, binding to TNF and preventing it from interacting with its cell surface receptors, thereby inhibiting its pro-inflammatory effects.
Opinercept Biosimilar works by blocking the activity of TNF, a cytokine that plays a crucial role in the development and progression of inflammatory and autoimmune diseases. TNF is known to promote inflammation, tissue damage, and joint destruction, making it a prime therapeutic target for these conditions.
By binding to TNF, Opinercept Biosimilar prevents it from binding to its cell surface receptors and initiating its downstream signaling pathways. This leads to a decrease in the production of pro-inflammatory cytokines and chemokines, reducing inflammation and providing relief from symptoms.
Opinercept Biosimilar has been extensively studied and has shown promising results in the treatment of various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease.
In clinical trials, Opinercept Biosimilar has demonstrated significant improvements in disease activity, physical function, and quality of life in patients with these conditions. It has also shown a favorable safety profile, with minimal adverse effects reported.
Opinercept Biosimilar is available in a research grade, making it an ideal tool for scientific studies and preclinical research. The high purity and potency of this biosimilar make it a valuable asset for studying the mechanisms of TNF inhibition and its effects on various disease models.
Research grade Opinercept Biosimilar can also be used to develop and optimize new therapeutic approaches for inflammatory and autoimmune diseases, providing a cost-effective and reliable option for researchers.
Opinercept Biosimilar is a revolutionary anti-TNF fusion protein that offers a new and effective treatment option for patients with inflammatory and autoimmune diseases. Its unique structure and mechanism of action make it a highly potent and safe therapeutic antibody. With its potential to improve patient outcomes and its applications in research, Opinercept Biosimilar is a promising addition to the arsenal of anti-TNF therapies.
ProteoGenix catalogue number PX-TA2020. For research use only.
Target: Opinercept Biosimilar – Anti-TNF fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Opinercept Biosimilar – Anti-TNF fusion protein – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
